A new Alzheimer’s drug: From advisory panel to FDA — what’s at stake here?

The FDA is in the process of deciding whether to approve a new drug to treat Alzheimer’s. Two large clinical trials produced contradictory results, but other factors will affect the decision, including cost, incidence of side effects, the drug’s effectiveness, and more.